Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)

Evaluation on Glycaemic Control and Weight Change of Once Daily Levemir® (Insulin Detemir) in Type 2 Diabetes Mellitus Treated by an Intensive Insulin Treatment (ICT)

This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.

Inclusion Criteria:

• Type 2 diabetic subjects on intensive insulin treatment (ICT)
• Eligibility for once daily insulin detemir administration
• Informed consent obtained before any observation-related activities

Exclusion Criteria:

• Known or suspected allergy to insulin detemir
• Subjects previously enrolled in the observation
• Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months.